NCT00963846View on ClinicalTrials.gov

Huperzine for Cognitive and Functional Impairment in Schizophrenia

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Schizophrenia
Interventions
DRUG

placebo

matching pill placebo

DRUG

huperzine 0.2 mg BID

huperzine rising doses up to 0.2 mg BID

DRUG

huperzine 0.4 mg BID

huperzine rising doses up to 0.4 mg BID

DRUG

huperzine 0.8 mg BID

huperzine rising doses up to 0.8 mg BID

Trial Locations (1)

06519

Yale University School of Medicine, New Haven

Sponsors
All Listed Sponsors
collaborator

Yale University

OTHER

lead

Biomedisyn Corporation

INDUSTRY

NCT00963846 - Huperzine for Cognitive and Functional Impairment in Schizophrenia | Biotech Hunter | Biotech Hunter